Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Peter Bretzman

Vascular & Interventional Radiology Edina, MN Medical Doctor

NPI 1902884117 CMS profile 702606

4100 Minnesota Dr. Suite 310, Ste 310, Edina, MN 55435

Open in the dashboard

General payments

$2,945

91 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Bretzman of Edina, MN is reported in the CMS Open Payments database as having received $2,945 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $604 15
2024 General $384 17
2023 General $1,034 36
2022 General $896 22
2021 General $28 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Bretzman
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Peter Bretzman were reported at $604. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Peter Bretzman Vascular & Interventional Radiology median Middle half National median
2019 $0 $422 $125–$1,555 $163
2020 $0 $200 $68–$652 $114
2021 $28 $280 $99–$866 $132
2022 $896 $433 $137–$1,497 $149
2023 $1,034 $506 $152–$2,019 $160
2024 $384 $556 $175–$1,930 $164
2025 $604 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $986 35 payments
  2. Medtronic, Inc. $720 18 payments
  3. Organogenesis Inc. $524 18 payments
  4. Siemens Medical Solutions USA, Inc. $182 2 payments
  5. Bard Peripheral Vascular, Inc. $149 3 payments
  6. Philips Electronics North America Corporation $63 1 payment
  7. Cardiovascular Systems Inc. $62 3 payments
  8. Mozarc Medical US LLC $61 2 payments
  9. Resmed Corp $44 2 payments
  10. Smith+Nephew, Inc. $35 1 payment
  11. Other $118 6 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,929 90 payments
  2. Travel and Lodging $16 1 payment
Products named General payments · program years 2021–2025
  1. Puraply $318 11 payments
  2. General - Therapies $288 4 payments
  3. MO.MA ULTRA $186 1 payment
  4. OSTEOCOOL RF ABLATION SYSTEM $150 1 payment
  5. INTELLIS ADAPTIVESTIM $108 2 payments
  6. SIMPLIMAX $104 1 payment
  7. RotarexS 6 F x 135 cm $92 1 payment
  8. Abre $74 2 payments
  9. JETSTREAM SC $72 4 payments
  10. Palindrome $65 2 payments
  11. Other $1,027 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

126

Median for Interventional Radiology: 38

Drug cost

$26,938

Median for Interventional Radiology: $333

Branded share of claims

74.6%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 44 $26,528
Clopidogrel Clopidogrel Bisulfate Brand 36 $228
Methylprednisolone Generic 19 $118
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 14 $32
Naproxen Generic 13 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 119 billing codes

Paid by Medicare

$559,451

Medicare's payments for the services billed

Medicare patients

292

Average age 73

Services billed

1,832

156 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 50%
Ischemic heart disease 29%
Chronic kidney disease 29%
Diabetes 27%
Cancer 27%
Depression 23%
Heart failure 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record